Global Biopharma Layoffs May 2026LayoffsBiopharma layoffs in 2026 continue to reshape the industry as companies including Takeda, Novartis, Replimune, Passage Bio and Autolus Therapeutics cut jobs, restructure operations and reduce costs amid pipeline setbacks, strategic reorganizations and market pressures.
Global Biopharma Layoffs March 2026LayoffsGlobal Biopharma companies including Merck, Baye, and Novartis announce workforce reductions in March 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
Novartis Full Year 2025 Financial ReportFinancial statementsNovartis' 2025 financial results show strong growth, driven by innovations like Kisqali, Pluvicto, and Leqvio. With a strong pipeline and key market expansions, the company is well-positioned for future growth despite patent challenges.
Global Biopharma Layoffs September 2025LayoffsThe biopharmaceutical industry sees major september layoffs, with companies like Novartis cutting jobs amid restructurings, trial setbacks, and M&A activity.
2025 H1 Global Pharma Earnings PanoramaFinancial statementsA comprehensive analysis of global pharma earnings in H1 2025, highlighting innovation-driven growth, key players like Novartis, Novo Nordisk, AstraZeneca, Sanofi, and BeiGene, and trends shaping the industry’s future.
Novartis Q2 2025 Earnings ReportFinancial statementsNovartis reported strong Q2 2025 results with double-digit revenue growth, key product successes, and promising R&D breakthroughs. The company's innovation and strategic focus position it for sustained long-term leadership.
Pharma's $158B U.S. Manufacturing SurgeMarket TrendMajor pharmaceutical companies pledge $158 billion to U.S. manufacturing to sidestep tariff threats, funding facilities from California to North Carolina. Lilly, J&J, Novartis, Roche and Regeneron drive billions in reshoring investments, creating thousands of jobs.
Novartis's Q1 2025 Financial report Market TrendNovartis reports strong Q1 2025 results with 12% sales growth, 27% core operating income increase, major FDA approvals, and raised full-year guidance amid robust innovation and strategic execution.
2024 Global Top 10 Pharmaceutical CompaniesMarket TrendThe 2024 global ranking of the top 10 pharmaceutical companies showcases the continued strength of industry leaders like Johnson & Johnson, Roche, and Merck. Pfizer, AstraZeneca, and Eli Lilly also maintain strong positions with impressive growth and strategic investments.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
